Answers are grounded in this paper and cite their sources.
Objectives: The aims of the present work were three-fold: 1) to compare the medicines' availability rate in Italy, France, England/Wales and the Netherlands; 2) to analyse the agreement level in coverage decisions; 3) to investigate whether divergent decisions are associated with the robustness of the pivotal study/ies or the added benefit.Methods: Medicines authorized by the EMA in 2020 and 2021 were selected.The first coverage decision regarding the first authorized indication(s) was extracted for each selected country and the availability rate was calculated.Cohen's Kappa scores were used to measure the concordance between national coverage decisions.Statistical associations were assessed using the Kendall rank correlation coefficient.Results: Overall, seventy-nine novel active ingredients and ninety-two medicine-indication pairs were identified.The availability rate varied between 80.4 percent and 62.0 percent.Only 19.0 percent of the medicine-indication pairs assessed by all HTA agencies were homogeneously appraised; when combining List and List with criteria into one single category "List", the share of pairs rose to 57.1 percent.Weighted Kappa scores confirmed poor agreement (weighted Kappa score <0.2).The level of agreement increased with the robustness of the pivotal study/ies, although the correlation was not statistically significant, while a weak positive correlation was found between the level of agreement and added benefit.
No takes yet. Share an insight, caveat, or question.
Cangini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: